Serological response to SARS‐CoV‐2 is attenuated in patients with inflammatory bowel disease and can affect immunization

In this study we indicated that impaired serological responses to SARS‐CoV‐2 infection among patients with IBD, could have significant implications for this group of patients and should be considered in vaccination program.[Image: see text]

Detalles Bibliográficos
Autores principales: Ghavami, Shaghayegh Baradaran, Shahrokh, Shabnam, Asadzadeh Aghdaei, Hamid, Khoramjoo, Seyed Mobin, Farmani, Maryam, Kazemifard, Nesa, Parigi, Tommaso Lorenzo, Danese, Silivio, Balaii, Hedieh, Sherkat, Ghazal, Ebrahimi Daryani, Nasser, Alborzi, Foroogh, Vossoughinia, Hassan, Zali, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021711/
https://www.ncbi.nlm.nih.gov/pubmed/35475199
http://dx.doi.org/10.1002/jgh3.12725
Descripción
Sumario:In this study we indicated that impaired serological responses to SARS‐CoV‐2 infection among patients with IBD, could have significant implications for this group of patients and should be considered in vaccination program.[Image: see text]

Ejemplares similares